FibroBiologics, Inc.
FBLG Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.95
KIRA · Stoqly’s AI analyst, in plain words
- FibroBiologics, Inc. lost $18.6M in fiscal 2025.
- Free cash flow was −$16.7M in fiscal 2025, — of revenue.
Market cap
$6.0M
P/E
0.4x
Revenue
—
Net income
−$18.6M
Free cash flow
−$16.7M
Operating margin
—
FibroBiologics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$18.6M
No. It lost money last year.
How is the share priced?
0.4x
One share costs 0.4 times its yearly profit per share.
What FibroBiologics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- FibroBiologics, Inc.
- CIK
- 0001958777
FibroBiologics, Inc. · FBLG
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$5.1M | −$16.5M | −$11.2M | −$18.6M |
| Diluted EPS | −$0.18 | −$0.68 | −$0.34 | −$0.42 |
| Cash | ||||
| Cash from operations | −$4.1M | −$6.4M | −$11.9M | −$16.4M |
| Capital expenditure | — | $0.5M | $0.2M | $0.3M |
| Free cash flow | — | −$6.9M | −$12.1M | −$16.7M |
| Share count change | — | 0.0% | 16.5% | 35.8% |
| Debt and strength | ||||
| Cash and short-term investments | $2.3M | $9.2M | $14.0M | $4.9M |
| Shareholders' equity | −$4.0M | $1.3M | $2.7M | $6.2M |
| Current ratio | 0.4x | 1.0x | 1.1x | 3.6x |
| Interest coverage | −6.8x | −60.5x | −686.9x | −81.6x |
| Returns and quality | ||||
| Return on equity | — | — | −559.7% | −419.4% |
| Return on tangible equity | — | −1,521.0% | −408.1% | −302.9% |
| Altman Z'' | −18.1 | −11.6 | −11.8 | −25.0 |
Insiders bought, 12 months
$0.1M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FibroBiologics, Inc. · FBLG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.95 a share, the company is worth $6.0M: 0.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001958777). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.